Back to search

Netherlands· NL-ff91504911f3

Pifeltro 100 mg filmomhulde tabletten

A doravirine product containing doravirine, registered in Netherlands by Merck Sharp & Dohme B.V.. The same ATC class is registered in 14 of our 19 countries.

ATC J05AG06

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedPifeltro 100 mg filmomhulde tablettenATCJ05AG06REGISTER NO.NL-ff91504911f3PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Doravirine is registered in 14 of 19 countries.

Countries holding a registration under ATC J05AG06 (doravirine), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 9 of them publish a price we can compare per daily dose

Doravirine · ATC J05AG06

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of doravirine costs, country by country.

Normalised to the WHO defined daily dose (0.1 g), the median price runs from $8.24 in France to $16.15 in Switzerland — a ×2.0 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Doravirine · price per daily dose (0.1 g)

USD · FX 28 Sept 2026

  • CH Switzerland$16.15
  • FR France$8.24
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
DORAVIRINE
Manufacturer
Merck Sharp & Dohme B.V.
Country
Netherlands (NL)
ATC code
J05AG06
ATC class
Doravirine
Defined daily dose
0.1 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/18/1332

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

88 interactions on record for doravirine.

Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Doravirine · interactions on record

88 records

  • 9 severe
  • 22 moderate
  • 57 minor

Most severe, free to view

  • DexamethasoneH02AB02severe
  • DabrafenibL01EC02severe
  • LorlatinibL01ED05severe
  • DabrafenibL01XE23severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Doravirine in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All doravirine products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Pifeltro
  • Liechtenstein · Pifeltro
  • Norway · Pifeltro

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f919206c-ee12-4051-b94a-15bae60d94cb
GET /v1/drugs/f919206c-ee12-4051-b94a-15bae60d94cb?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/pifeltro-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Doravirine",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp122171",
  "excipients": [
    "CARNAUBAWAS (E 903)",
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "GLYCEROLTRIACETAAT (E 1518)",
    "HYPROMELLOSE (E 464)",
    "HYPROMELLOSEACETAATSUCCINAAT",
    "LACTOSE 1-WATER",
    "MAGNESIUMSTEARAAT (E 470b)",
    "SILICIUMDIOXIDE (E 551)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "DORAVIRINE"
  ],
  "leaflet_url": null,
  "authorised_at": "2018/11/22",
  "procedure_number": "EMEA/H/C/004747",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/18/1332",
  "additional_monitoring": "N"
}

See everything about doravirine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.